Related Experiment Video
Updated: Aug 8, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Cancer vaccines: an update
J D Hipp1, J A Hipp, B W Lyday
1Cancer Center, University of California-San Diego, La Jolla, CA 92093-0060, USA.
Abstract:
This review summarizes the most recent findings and the future directions in designing cancer vaccines. The newest tumor-associated antigens and the most promising approaches to cancer vaccine development are discussed. We categorized them as follows: peptide vaccines, recombinant viral vaccines, DNA vaccines, dendritic cell-based immunotherapy, and the use of heat shock proteins and adjuvants. We focus on their advantages and disadvantages in addition to clinical potential.
Insights
This review explores cutting-edge cancer vaccine designs, including peptide, viral, and DNA vaccines, alongside dendritic cell immunotherapy. It highlights promising tumor antigens and future directions for effective cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer vaccines represent a promising avenue for targeted cancer treatment.
- Developing effective cancer vaccines requires identifying suitable tumor-associated antigens and optimal delivery platforms.
Purpose of the Study:
- To review recent advancements in cancer vaccine design.
- To discuss emerging tumor-associated antigens and promising vaccine development approaches.
- To evaluate the clinical potential, advantages, and disadvantages of various vaccine strategies.
Main Methods:
- Literature review of recent findings in cancer vaccine research.
- Categorization of vaccine approaches: peptide vaccines, recombinant viral vaccines, DNA vaccines, dendritic cell-based immunotherapy, heat shock proteins, and adjuvants.
Main Results:
- Identification of novel tumor-associated antigens.
- Evaluation of diverse vaccine platforms including peptide, viral, DNA, and cellular immunotherapies.
- Analysis of the strengths and weaknesses of each approach regarding clinical application.
Conclusions:
- Cancer vaccine development is rapidly advancing with diverse and promising strategies.
- Peptide, viral, DNA vaccines, and dendritic cell-based approaches show significant clinical potential.
- Future research should focus on optimizing these platforms and understanding their therapeutic efficacy in various cancers.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...